title: Magnetic resonance contrast media sensing in vivo molecular imaging agents: an overview.
abstract: Metabolic imaging is commonly performed by nuclear medicine facilities such as PET or SPECT, etc. The production and biomedical applications of bio-molecular sensing in vivo MRI metabolic contrast agents has recently become of great universal research interest, which follows its great success as a potential cost effective, less radioactive, nuclear medicine alternative. Temperature, redox potential, enzyme activity, free radial/metal ion responsive and/or pH sensitive molecular metabolic MR contrast agents are among the famous instances exemplified, which basically promote MR image contrast enhancement ability to distinguish molecular metabolic/gene expression features. Overall, these MRI contrast agents provide a framework to achieve a greater degree of accuracy from MRI as a low cost, more available facility, non radioactive radiation producing and highly sensitive biomedical tool to propound as a new suggesting opponent for PET nuclear medicine imaging. In the present review, the design, development, examination and future of the above agents will be discussed in detail.
authors.affiliation: Hepatitis and AIDS and Nanobiotechnology Department, Pasteur Institute of Iran, Tehran, Iran.
authors.forename: Massoud
authors.initials: M
authors.lastname: Amanlou
authors.forename: Seyed Davar
authors.initials: SD
authors.lastname: Siadat
authors.forename: Dariush
authors.initials: D
authors.lastname: Norouzian
authors.forename: Seyed Esmaeil Sadat
authors.initials: SE
authors.lastname: Ebrahimi
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Aghasadeghi
authors.forename: Masoud
authors.initials: M
authors.lastname: Ghorbani
authors.forename: Mohammad Shafiee
authors.initials: MS
authors.lastname: Alavidjeh
authors.forename: Davoud Nouri
authors.initials: DN
authors.lastname: Inanlou
authors.forename: Ali Jabbari
authors.initials: AJ
authors.lastname: Arabzadeh
authors.forename: Mehdi Shafiee
authors.initials: MS
authors.lastname: Ardestani
mesh_terms: D000284:Administration, Oral; D000911:Antibodies, Monoclonal / Q000737:chemistry; D001853:Bone Marrow / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D003287:Contrast Media / Q000008:administration & dosage / Q000138:chemical synthesis; D004337:Drug Carriers / Q000138:chemical synthesis / Q000737:chemistry; D005290:Ferric Compounds / Q000378:metabolism; D005947:Glucose / Q000493:pharmacokinetics; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008081:Liposomes / Q000138:chemical synthesis / Q000737:chemistry; D008198:Lymph Nodes / Q000378:metabolism; D008279:Magnetic Resonance Imaging / Q000379:methods*; D057054:Molecular Imaging / Q000379:methods*; D058990:Molecular Targeted Therapy; D010455:Peptides / Q000378:metabolism; D010743:Phospholipids / Q000138:chemical synthesis / Q000737:chemistry; D011108:Polymers / Q000138:chemical synthesis; D049268:Positron-Emission Tomography
chemical_list: D000911:Antibodies, Monoclonal; D003287:Contrast Media; D004337:Drug Carriers; D005290:Ferric Compounds; D008081:Liposomes; D010455:Peptides; D010743:Phospholipids; D011108:Polymers; C000499:ferric oxide; D005947:Glucose